APA (7th ed.) Citation

Cheng, Y., Zhang, P., Lu, M., Chen, Z., Song, L., Shi, S., . . . Zhong, C. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: An open-label, single-arm, multicenter, multi-cohort phase II trial. Springer.

Chicago Style (17th ed.) Citation

Cheng, Ying, et al. Efficacy and Safety of Surufatinib Plus Toripalimab in Treatment-naive, PD-L1-positive, Advanced or Metastatic Non-small-cell Lung Cancer and Previously Treated Small-cell Lung Cancer: An Open-label, Single-arm, Multicenter, Multi-cohort Phase II Trial. Springer.

MLA (9th ed.) Citation

Cheng, Ying, et al. Efficacy and Safety of Surufatinib Plus Toripalimab in Treatment-naive, PD-L1-positive, Advanced or Metastatic Non-small-cell Lung Cancer and Previously Treated Small-cell Lung Cancer: An Open-label, Single-arm, Multicenter, Multi-cohort Phase II Trial. Springer.

Warning: These citations may not always be 100% accurate.